Thus, by deciphering the complex regulatory mechanisms of spastin and exploiting the druggability of CRL4, we can pave the way for novel therapeutic interventions, offering new hope for improved clinical outcomes in SPG4-HSP patients. This evidence concerns the gene IL17RB and hereditary spastic paraplegia.